BioSpace News Archive

According to the Super Doctor’s Website, “In selecting physicians for Super Doctors, MSP Communications employs a rigorous multi-step process designed to identify physicians who have attained a high degree of peer recognition and professional achievement.”

Neuren Pharmaceuticals announced that the US Food and Drug Administration has granted Orphan Drug Designation to Neuren’s NNZ-2591 for the treatment of Angelman syndrome, Phelan-McDermid syndrome and Pitt Hopkins syndrome.

Results from early access collaborators show high quality and reproducibility

ChromaDex Corp. announced that the results of a preclinical study conducted by Nestlé were published last month in the journal Nature Communications, a peer-reviewed open access scientific journal published by the Nature Publishing Group.

NeuroMetrix, Inc. reported financial and business highlights for the quarter ended September 30, 2019.

Arvinas Inc.,, a biotechnology company creating a new class of drugs based on targeted protein degradation, announced it will be participating in multiple sessions of the 2nd Targeted Protein Degradation Summit.

Allergan plc announced it will release third quarter 2019 financial results on Tuesday, November 5, 2019, prior to the open of U.S.

Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that long-term efficacy and safety characterization results for KEVEYIS® (dichlorphenamide), the first and only U.S. Food and Drug Administration (FDA) approved treatment for hyperkalemic, hypokalemic

Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), today announced interim top-line results at 12 weeks from the first cohort of the ongoing Phase 2 trial evaluating the safety, efficacy and pharmacodynamics of escalating doses (50mg, 200mg and 400mg) of the investigational compound inarigivir co-administered with Gilead Sciences’ Vemlidy® (tenofovir alafenamide 25mg) for the treatment of chronic hepatitis B virus (HBV) infection.

BeyondSpring Inc. announced that the United States Patent Office has granted the Company a new patent, U.S. Patent No. 10,357,491 B2, for methods of treating a brain tumor by administering Plinabulin..